U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H5ClN2O
Molecular Weight 168.58
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZOXAZOLAMINE

SMILES

NC1=NC2=CC(Cl)=CC=C2O1

InChI

InChIKey=YGCODSQDUUUKIV-UHFFFAOYSA-N
InChI=1S/C7H5ClN2O/c8-4-1-2-6-5(3-4)10-7(9)11-6/h1-3H,(H2,9,10)

HIDE SMILES / InChI
Zoxazolamine is a centrally acting muscle relaxant. It decreased striatal dopamine metabolism without affecting striatal dopamine concentrations. More specifically, Zoxazolamine was shown to decrease striatal dopamine turnover without directly affecting dopamine synthesis, catabolism, reuptake, or release. It is the IK(Ca) channel opener. It was approved for the relief of muscle spasm in conditions such as musculoskeletal disorders and neurological diseases. Later, it was submitted for the drug's use as a uricosuric agent to treat gout. It was withdrawn from the market due to hepatotoxicity.

Originator

Sources: DOI: 10.1021/ja01107a511

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Flexin

Approved Use

Zoxazolamine was indicated as a uricosuric agent to treat gout.

Launch Date

1956
Primary
Flexin

Approved Use

Zoxazolamine was indicated for the relief of muscle spasm in conditions such as musculoskeletal disorders and neurological diseases

Launch Date

1956
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.5 mg/L
1 g single, oral
dose: 1 g
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOXAZOLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
250 mg 4 times / day multiple, oral (starting)
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy, 40 years
n = 1
Health Status: unhealthy
Condition: chronic polyartieular gout
Age Group: 40 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Hepatitis...
AEs leading to
discontinuation/dose reduction:
Hepatitis (acute, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hepatitis acute, 1 patient
Disc. AE
250 mg 4 times / day multiple, oral (starting)
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy, 40 years
n = 1
Health Status: unhealthy
Condition: chronic polyartieular gout
Age Group: 40 years
Sex: M
Population Size: 1
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Effect of microsomal enzyme inducers on the biliary excretion of cardiac glycosides.
1974 Nov
Effect of benzopyrone derivatives on drug activity and metabolism.
1986 Oct-Dec
Pharmacological activation of cloned intermediate- and small-conductance Ca(2+)-activated K(+) channels.
2000 Mar
Aryl hydrocarbon receptor signaling plays a significant role in mediating benzo[a]pyrene- and cigarette smoke condensate-induced cytogenetic damage in vivo.
2001 Jan
Modulation of recombinant small-conductance Ca(2+)-activated K(+) channels by the muscle relaxant chlorzoxazone and structurally related compounds.
2001 Mar
Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor.
2001 Nov
Moricizine, an antiarrhythmic agent, as a potent inhibitor of hepatic microsomal CYP1A.
2002 Dec
Stimulatory effects of chlorzoxazone, a centrally acting muscle relaxant, on large conductance calcium-activated potassium channels in pituitary GH3 cells.
2003 Jan 3
Unexpected down-regulation of the hIK1 Ca2+-activated K+ channel by its opener 1-ethyl-2-benzimidazolinone in HaCaT keratinocytes. Inverse effects on cell growth and proliferation.
2003 Jan 31
Functional and molecular identification of intermediate-conductance Ca(2+)-activated K(+) channels in breast cancer cells: association with cell cycle progression.
2004 Jul
Effect of some biologically interesting substituted tetrahydro-1,4-oxazines on drug metabolising enzymes and on inflammation.
2005 Oct
Gender-specific induction of cytochrome P450s in nonylphenol-treated FVB/NJ mice.
2006 Oct 15
Hepatoprotective potential of Aloe barbadensis Mill. against carbon tetrachloride induced hepatotoxicity.
2007 May 22
Molecular and cellular basis of small--and intermediate-conductance, calcium-activated potassium channel function in the brain.
2008 Oct
Constitutive androstane receptor mediates the induction of drug metabolism in mouse models of type 1 diabetes.
2009 Aug
9,9-Dimethyl-12-(4-nitro-phen-yl)-9,10-dihydro-12H-benzo[a]xanthen-11(8H)-one.
2009 Nov 21
Bioenhancers: Revolutionary concept to market.
2010 Apr
Patents

Patents

Sample Use Guides

0.5 gm daily dose
Route of Administration: Oral
Mouse aortic endothelial cells were loaded with 0.5 uM Ca2+ in the pipette and current measured at 50 and −50 mV during repetitive ramps and the corresponding I/V curves constructed. 100 uM of zoxazolamine activated the K(Ca) current.
Name Type Language
ZOXAZOLAMINE
INN   MI  
INN  
Official Name English
URI-BOI
Brand Name English
NSC-24995
Code English
FLEXIN
Brand Name English
ZOXAZOLAMINE [MI]
Common Name English
MIAZOL
Brand Name English
5-CHLORO-2-BENZOXAZOLAMINE
Systematic Name English
CONTRAZOLE
Brand Name English
ZOXAMINE
Brand Name English
ZOXINE
Brand Name English
MCN-485
Code English
zoxazolamine [INN]
Common Name English
2-AMINO-5-CHLOROBENZOXAZOLE
Systematic Name English
DEFLEXOL
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C921
Created by admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
NCI_THESAURUS C29696
Created by admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
Code System Code Type Description
MESH
D015049
Created by admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
PRIMARY
NSC
24995
Created by admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
PRIMARY
EVMPD
SUB00192MIG
Created by admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
PRIMARY
NCI_THESAURUS
C152966
Created by admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
PRIMARY
PUBCHEM
6103
Created by admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
PRIMARY
MERCK INDEX
m11669
Created by admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
PRIMARY Merck Index
ChEMBL
CHEMBL472566
Created by admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
PRIMARY
FDA UNII
9DOW362Q29
Created by admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
PRIMARY
EPA CompTox
DTXSID1045245
Created by admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
PRIMARY
INN
524
Created by admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
PRIMARY
SMS_ID
100000078820
Created by admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
PRIMARY
DRUG CENTRAL
2876
Created by admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
PRIMARY
CAS
61-80-3
Created by admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
PRIMARY
WIKIPEDIA
Zoxazolamine
Created by admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-519-4
Created by admin on Fri Dec 15 15:03:44 GMT 2023 , Edited by admin on Fri Dec 15 15:03:44 GMT 2023
PRIMARY